Edition:
United States

Zealand Pharma A/S (ZELA.CO)

ZELA.CO on Copenhagen Stock Exchange

91.00DKK
19 Feb 2018
Change (% chg)

kr.0.20 (+0.22%)
Prev Close
kr.90.80
Open
kr.91.50
Day's High
kr.92.30
Day's Low
kr.90.50
Volume
64,107
Avg. Vol
130,386
52-wk High
kr.141.00
52-wk Low
kr.78.50

Chart for

About

Zealand Pharma A/S is a Denmark-based biopharmaceutical company engaged in the discovery, development and commercialization of peptide-based medicines. The Company's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and... (more)

Overall

Beta: 0.98
Market Cap(Mil.): kr.2,792.22
Shares Outstanding(Mil.): 30.75
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Zealand Reports Royalty Revenue Of DKK 11.3 Mln For Q4 2017

* REG-ZEALAND REPORTS ROYALTY REVENUE FOR THE FOURTH QUARTER OF 2017

Feb 07 2018

Biotech Zealand Pharma bets on self-marketing over big pharma partnerships

GLOSTRUP, Denmark, Jan 30 Denmark's Zealand Pharma is pinning its strategy on rare disease drugs that the small biotech can market itself after seeing disappointing income from a diabetes drug marketed by partner Sanofi, its chief executive said.

Jan 30 2018

BRIEF-Zealand: Clinical Evidence Support Potential For Glepaglutide

* ZEALAND HAS COMPLETED A PHARMACOKINETIC (PK) STUDY WITH GLEPAGLUTIDE THAT CONFIRMS POTENTIAL FOR ONCE-WEEKLY DOSING

Jan 23 2018

BRIEF-Zealand Pharma Announces Progress To Phase 3 With Dasiglucagon For The Treatment Of Congenital Hyperinsulinism

* ZEALAND PHARMA ANNOUNCES PROGRESS TO PHASE 3 WITH DASIGLUCAGON FOR THE TREATMENT OF CONGENITAL HYPERINSULINISM IN FIRST HALF 2018

Jan 19 2018

BRIEF-Zealand Pharma Makes Initial USD 1.5 Mln Equity Investment In Beta Bionics

* ZEALAND PHARMA MAKES AN INITIAL USD 1.5 MILLION EQUITY INVESTMENT IN SERIES B OFFERING OF BETA BIONICS, INC.

Dec 21 2017

BRIEF-Zealand Pharma Initiates Phase 3 Trial With Dasiglucagon

* ZEALAND PHARMA INITIATES THE PIVOTAL PHASE 3 TRIAL WITH DASIGLUCAGON FOR THE TREATMENT OF SEVERE HYPOGLYCEMIA IN DIABETES

Dec 07 2017

BRIEF-Zealand Pharma Q3 operating loss at DKK 38.2 mln ​

* ‍MAINTAINS ITS REVENUE GUIDANCE OF A CONTINUED INCREASE IN ROYALTY PAYMENTS FROM SANOFI.​

Nov 08 2017

BRIEF-Zealand reports royalty revenue Of DKK 10.3 mln for Q3

* REG- ZEALAND REPORTS ROYALTY REVENUE FOR THE THIRD QUARTER OF 2017

Nov 02 2017

BRIEF-Zealand Pharma granted orphan drug designation by FDA

* REG-U.S. FDA GRANTS ORPHAN DRUG DESIGNATION TO GLEPAGLUTIDE FOR THE TREATMENT OF SHORT BOWEL SYNDROME

Oct 24 2017

New Zealand forestry a first test in nationalist party's protectionist agenda

WELLINGTON Some New Zealand forest owners are suspending replanting of trees and re-thinking investments as the country's third-largest export earner finds itself in the sights of maverick politician Winston Peters' protectionist agenda.

Oct 10 2017

Earnings vs. Estimates